Kornimate/medical-research-clean huggingface dataset:
effect of oral magnesium therapy on constipation on cerebral palsy children

Conditions: Magnesium Therapy on Cerebral Palsy Patients

Summary: the aim of this study is to study the therapeutic and adverse effects of oral magnesium sulfate therapy on constipation in children with spastic cerebral palsy suffering from chronic constipation in neuro pediatric unit at assiut university hospital.

children with cerebral palsy (cp) often experience many comorbidities such as constipation,which is considered a frequent problem in spastic (cp)children .it occurs due to reduced mobility, difficulties in feeding and as a side effect of many muscle relaxing medications.it is estimated that 74% of children with cerebral palsy suffer from constipation ,which necessitates use of laxatives. magnesium sulfate has a famous role as being an osmotic laxative,which is the first step in the pharmacological treatment of constipation • mechanism of action of mg sulphate: they are poorly absorbed by the intestinal wall, which leads to intraluminal accumulation of hyperosmolar particles. this stimulates retention of water in the intestinal lumen, softening the stools and increasing peristalsis through intestinal distension. it acts by accelerating small intestinal transit both in fasting and in fed state and it tends to increase the frequency and weight of stools, compared with placebo.in addition ,it increases intraluminal secretion of cholecystokinin and increases nitric oxide (no) release. • side effects of mg sulphate: reducing the intestinal absorption of fat, protein and carbohydrates following solid meal ingestion • other drugs used as laxative in cp and there side effects: * lactulose: it can lead to distention, bloating and excess flatus. in some individuals these side-effects may limit the use of this product. * glycerin: is another small molecule that can exert osmotic activity in the colon. it is not absorbed by the colon and is used as a suppository to draw water into the rectum to produce a bowel movement. it is well absorbed by the small intestine, and hence cannot be taken by oral route. * the aim of this study is to study the therapeutic and adverse effects of oral magnesium sulfate therapy on constipation in children with spastic cerebral palsy suffering from chronic constipation in neuro pediatric unit at assiut university hospital.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed as cerebral palsy 2. age below18 year 3. presence of constipation according to rome criteria exclusion criteria: 1. patients with cardiac problem 2. patients with renal problem 3. patients with git problem or chronic diarrhea
effect of pasta on blood glucose response in normal subjects

Conditions: Blood Glucose Concentration; Type 2 Diabetes; Metabolic Syndrome

Summary: the objective of this study is to determine whether ingestion of modified pasta products (dreamfields, miracle noodles) result in an improvement in blood glucose concentration when compared with a traditional pasta.

on one occasion the pasta will be a traditionally available pasta; on another occasion, approximately 1 week later a modified pasta, advertised to contain \~ 5 grams of digestible carbohydrate, or to be low in digestible starch, will be studied.

Eligibility criteria:
inclusion criteria: * normal blood glucose concentration

Keywords: low biologically available glucose diet (lobag diet) diabetes glycemic index
etanercept therapy for nails psoriasis monitoring with noninvasive imaging

Conditions: Psoriasis; Psoriatic Arthritis; Psoriatic Nail

Summary: optiskin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with enbrel® (etanercept) with optical coherence tomography (oct).

psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to infections. these symptoms can be difficult to manage, so optiskin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with enbrel® (etanercept) with optical coherence tomography (oct). oct is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis. study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.

Eligibility criteria:
inclusion criteria: * moderate to severe psoriasis * psoriasis affecting the fingernails exclusion criteria: * previous treatment with enbrel® (etanercept) * active infection * rheumatoid arthritis * any personal or family history of any neurologic demyelinating disease * receipt of investigational drugs or "biologics" within 4 weeks of the screening visit

Keywords: psoriasis nails psoriatic arthritis enbrel biologic
the safety and effectiveness of u-90152 in hiv-1 infected patients who take zidovudine

Conditions: HIV Infections

Summary: to evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( u-90152 ) after multiple doses given orally to asymptomatic hiv-1 positive patients who are maintained on a stable dose of zidovudine ( azt ). to investigate the optimum dose regimen of u-90152 that gives average trough concentrations \> 1 micromolar in combination with standard azt therapy, and to examine drug interactions between the two drugs. to establish the mtd of u-90152 in hiv-1 positive patients on stable azt therapy. to investigate comparative pharmacokinetics between hiv-1 positive men and women.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * inhaled pentamidine following completion of the inpatient pharmacokinetic portion of the study. patients must have: * hiv-1 infection. * cd4 count 200 - 500 cells/mm3. * maintenance on azt for at least 6 weeks. * no active opportunistic infections. * ability to swallow numerous tablets without difficulty. * ability to have blood samples drawn. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * acute medical problems, including opportunistic infections (such as active cryptococcosis, pneumocystis carinii, herpes zoster, histoplasmosis, cmv) and nonopportunistic diseases (liver and renal disease, orthostatic hypotension, hypertension, progressive multifocal leukoencephalopathy, lymphoma, kaposi's sarcoma, or other malignancy). * clinically significant hypersensitivity to piperazine type drugs (antepar, stelazine, and u-87201e). * negative emit drug screen or equivalent for drugs of abuse. concurrent medication: excluded: * antiretroviral agents other than azt. * primary or secondary prophylactic medications for opportunistic infections (inhaled pentamidine is permitted following completion of the inpatient pharmacokinetic portion of the study). patients with the following prior conditions are excluded: * history of clinically significant nervous system or muscle disease, seizure disorder, aids dementia, or psychotic disorder that might impair study compliance. * history of clinically significant cardiovascular, renal, hepatic, cardiac, pulmonary, endocrine, hematologic, vascular, or collagen disease. prior medication: excluded: * prior u-87201e or other non-nucleoside reverse transcriptase inhibitors (nevirapine, tibo, l-drugs, and hept). * antiretroviral agents (other than azt) or immunomodulating agents within 15 days prior to study entry. * primary prophylactic drugs within 15 days prior to study entry. * any known enzyme-inducing drug or any enzyme-inhibiting agents, such as ketoconazole, fluconazole, rifampin, isoniazid, and cimetidine, within 15 days prior to study entry. * any investigational medication within 15 days prior to study entry. unwilling to comply with safer sex practices. active substance abuse. alcohol consumption during the inpatient pharmacokinetic portion of the study.

Keywords: drug interactions antiviral agents zidovudine
color doppler and mri diffusion in major salivary gland masses

Conditions: Salivary Gland Diseases

Summary: this study intend to evaluate the combined value of adc and color doppler in differentiating benign and malignant salivary gland tumors in comparison to histopathological findings and its use in preoperative prediction of benign and malignant masses.

the study aim to achieve preoperative differentiation between benign and malignant masses of the major salivary glands using the adc values and color doppler values (psv - pi - ri)

Eligibility criteria:
inclusion criteria: 1- patients must be 18 of age or older. 2= patients must have a suspicious swelling in major salivary glands. exclusion criteria: 1. patients with history of metal plates or screws or artificial joints. 2. patients who have phobia of indoor places. 3. patients with contraindication to mri like intra-cerebral aneurysmal clips, cardiac pacemaker, and metallic foreign body at region of examination.
the effect of online peer and adult education given to adolescents with allergic asthma

Conditions: Self Efficacy; Asthma; Asthma in Children

Summary: objectives: to examine the effect of interactive online education given by peers or adults on anxiety, self-efficacy, quality of life, and disease knowledge and management in adolescents with allergic asthma in the 10-14 age group. methods: the research was conducted as a randomized controlled study. the study sample consisted of 84 adolescents divided into experimental groups \[receiving peer(n=28) or adult(n=28) education\] and control(n=28) group. the adolescents in the peer or adults were given online interactive education concerning allergic asthma and the management thereof. the control group received only usual training.data were collected using an adolescent personal data form, the state anxiety inventory for children, the self-efficacy scale for children and adolescents with asthma, the pediatric asthma quality of life questionnaire, and the disease knowledge and management questionnaire. data were collected from the adolescents before (t0) and immediately after education (t1), and after one (t2) and three months (t3). this study is a non-blinded randomized controlled trial. . all screened adolescents with asthma were randomly assigned to one of the three groups: the peer or adults education groups that received a 6 weeks asthma education and a control group that received usual care. the three groups were then followed prospectively immediately, 1, and 3 months after training to evaluate the effectiveness of training compared with usual care.


Eligibility criteria:
inclusion criteria: age was 10 to 14 years, doctor-diagnosed allergic asthma, without allergic rhinitis with a diagnosis of allergic asthma (by medical record), internet access via computer or phone, the ability to speak turkish, willingness to participate. exclusion criteria were those with moderate to severe cognitive or mental health impairment and a diagnosis of allergic rhinitis in addition to the diagnosis of allergic asthma (according to medical records).

Keywords: adolescent anxiety asthma knowledge self-efficacy quality of life
long-term treatment study of mra for systemic juvenile idiopathic arthritis (sjia)

Conditions: Systemic Juvenile Idiopathic Arthritis

Summary: an open-label, extension, phase iii study to evaluate the long-term safety and efficacy of mra in patients with sjia who were participated in studies mra011jp or mra316jp


Eligibility criteria:
inclusion criteria (mra011jp patients) * of the patients who received the three infusions of mra at the same dose in the main evaluation period in the previous study and are currently in the continued treatment period * the patients in whom it is confirmed that the drug is effective and there are no problems with safety (mra316jp patients) * patients who proceed to the blind period and in whom the last observations are done after study completion or withdrawal * patients who receive the three infusions in the open-label period and do not meet the criteria for transition to the blind period exclusion criteria * patients who were not enrolled by 3 months after completion of the previous study * patients who have been treated with infliximab or etanercept from completion of the previous study until the start of treatment in this study
dissecting how peripheral lymphocytes are lost during sepsis

Conditions: Sepsis

Summary: there is an observational, clinical study. we recruit sepsis patients to investigate what drives peripheral lymphocyte loss in sepsis.

there is an observational, clinical study. we recruit patients with diagnosis of new onset sepsis within 24h, collect and record clinical characteristics： ①demography data，diagnosis, admission source, infection source, apache ii,sofa scores;②endotoxin levels and pao2 measured;③immune and systemic inflammatory indicators：t, rr, wbc, alc, etc.;④complicated organs dysfunctions: duration and therapy;⑤incidence of icu-acquired infection and prognosis.the blood samples were collected for apoptosis,necrosis,autophagy,pyroptosis measurements.the aim of this study is to investigate how peripheal lymphocyte loss relates to outcome and the mechanisms of peripheal lymphocyte loss in different condition.

Eligibility criteria:
inclusion criteria: * health volunteers exclusion criteria: * history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.

Keywords: sepsis, lymphocyte
functional ability, symptoms and quality of life in patients with post covid-19 condition

Conditions: Post Covid-19 Condition

Summary: up to 20% of patients with covid-19 develop symptoms that last more than 3 months, which is known as long covid or post-covid-19 condition. the mechanism of the long term symptoms is not totally understood although inflammation, autoimmune reactions and thromboembolism are among suspected contributors. at helsinki university hospital, a long covid clinic was opened in june 2021. the aim of this cohort study is to monitor the patients that attend the clinic, follow up their functional abilities, quality of life and prognosis.

the patients are asked to give their informed consent for the participation in the cohort study. they fill in a questionnaire before entering the clinic that assesses their symptoms, previous medical history, medications, lifestyle, symptoms, sleep, psychosocial measures including depression, anxiety, resilience and quality of life. the patients are asked to give blood samples that rule out other diseases that may cause the symptoms. at the clinic, they attend a physician's consultation with physical exam. later, in another apppointment, a physicotherapist assesses their physicial functioning including 6 minutes walking test and grip strength. they also attend a psychologist who conducts short, 30 min neuro-cognitive testing. patients receive psychoeducation of the post covid-19 condition and individual, tailored support and rehabilitation. they are given the opportunity to take part in group counselling once a week during 6 weeks. the patients are followed up by nurse telephone calls at 3, 6 and 12 months as well as by questionnaires via a secured website. the main outcome measure in this study is functional ability as measured by whodas2.0.

Eligibility criteria:
inclusion criteria: * a diagnosed covid-19 infection at least 3 mo before entry (either pcr positive or antigen test positive or hospitalisation because of covid-19) exclusion criteria: * patients for whom participation would be too exhausting, for example bed patients * patients who cannot fill in the questionnaires in finnish

Keywords: post covid-19 condition long covid
prospective case series to assess complications of using distal ulna locking plate of i.t.s.

Conditions: Ulna Fractures

Summary: background of the study: various studies show that the outcome of unstable distal ulna fractures after open reduction and internal fixation is better than closed reduction. the previous plate system for the distal ulna fractures is applied exclusively on the extensor side. this often leads to irritation of the extensor tendons, as well as problems with pronation and supination. with the new shape of the angle-stable distal ulna plate, the investigator hopes that the stability of the fracture osteosynthesis will remain the same and that it will be better tolerated with regard to the surrounding soft tissue, especially the extensor tendons. in this way, an otherwise practically unavoidable removal of osteosynthesis material could - at least in some cases - be avoided and some patients spared a follow-up operation. with this in mind, the investigator tries to achieve the greatest possible reconstruction and stability for early functional follow-up treatment with a slightly bulky implant placed in the tendon-free area.

with this study, the application and usability of the new angle-stable plate system should be determined and documented. new value of the study: this system enables an optimal position of the plate on the distal ulna, on the one hand due to the position on the flexor side and on the other hand due to the new shape, adapted to the anatomy of the distal ulna. the locking system using angle-stable screws corresponds to the systems previously used by i.t.s. design: prospectively, handling, advantages and possible complications of the angle-stable, distal ulna plate; company i.t.s. in the osteosynthesis of the unstable distal ulna fracture. a total of 20 patients with unstable distal ulna fractures are to be treated and evaluated over a period of 12 months according to the study design. risk/benefit: with the use of the angle-stable distal ulna plate, company i.t.s. the patients broken bone may heal better. however, it is also possible that the patient will not benefit directly from his/her participation in this clinical trial. the expected benefit of the locking distal ulnar plate; company i.t.s. includes: * reduced risk of bone misalignment after surgery. * less risk of irritating tendons on the plate with the new location. * a removal of the osteosynthesis material could possibly be avoided.

Eligibility criteria:
inclusion criteria: 1. age over 18 years 2. unstable distal ulna fractures fracture classification according to biyani \[4\]: all types exclusion criteria: 1. age under 18 years old 2. stable fractures of the ulna 3. patient had one before ulna fracture 4. patient may result in physical or intellectual disability consent not grant 5. patient is for more check-ups not available (abroad) 6. patient does not have full legal capacity 7. alcohol and drug abuse 8. increased risk of anesthesia (from asa 3)
otitis treatment with otosight™ - modification of antibiotic treatment intervention in children

Conditions: Otitis Media Acute

Summary: a pragmatic, mixed-method trial is to show the ability of otosight to change management of the pediatric patient presenting with ear pain in a way that improves patient outcomes and reduces costs.

mixed method, multi-center, pragmatic, cluster-randomized effectiveness-implementation investigation focused on pediatric subjects presenting with ear complaints at the office setting. for the prospective randomized component, eligible clinicians at a given site will be randomized to one of two groups: the otosight intervention group or the usual care control group. there will be three (3) periods of post-intervention assessment: 10 days (optional), 6 months, and 12 months. eligible subjects will be automatically enrolled (or invited to enroll) in the clinical trial and will receive information. because this is a non-interference design, frontline care clinicians randomized to either arm will be asked to: (1) assess the presence or absence of fluid in the middle ear; (2) record a diagnosis; and (3) treat the patient as they would according to the information available to them. a separate retrospective historical matched control arm will also be conducted to analyze potential hawthorne effect at a subset of collaborating practices or healthcare systems. randomization of clinicians (and not children) will decrease contamination in the usual practice group (i.e., so clinicians are not asked to flip between intervention and usual care practices).

Eligibility criteria:
inclusion criteria: * pediatric subjects between 6 months and 17 years of age * pediatric subjects presenting for an office visit with ear-related pain (otalgia)/otic complaints/earache indicative of potential otitis media with effusion (ome) or acute otitis media (aom) * pediatric subjects where otoscopy would traditionally be indicated * pediatric subjects whose parents or legally authorized representative (lar) have signed an informed consent exclusion criteria: * the parent or guardian who attends visits does not speak the same language as their physician * pediatric subjects enrolled in another clinical trial * pediatric subjects with: * signs of severe chronic illness (e.g., immunodeficiency, congenital heart disease, encephalopathy, pulmonary disease other than asthma, and disorder of the ear, nose and throat) or any clinically significant illness or condition that, in the opinion of the investigator, would prohibit the subject from participating in the trial * anatomical conditions that would affect their ability to undergo an otoscopy.

Keywords: otitis media with effusion ear infection optical coherence tomography otitis media machine learning
dosing of levetiracetam (keppra) in neonates

Conditions: Seizures

Summary: the primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg loading dose of intravenous levetiracetam (lev) in term and late preterm infants with seizures. secondary objectives are to evaluate the safety and efficacy of a 50 mg/kg loading dose of levetiracetam in term and preterm infants with seizures, and to obtain data on steady state drug levels of levetiracetam in neonates.


Eligibility criteria:
inclusion criteria: * gestational age ≥ 32 weeks * postnatal age ≤ 30 days * birth weight ≥ 2000 grams * admitted to the neonatal intensive care unit at cincinnati children's hospital * clinical or electrographic seizures of any etiology * seizures or seizure prophylaxis requiring treatment with levetiracetam * parental consent obtained exclusion criteria: * infants with renal insufficiency indicated by serum creatinine \> 2.0 at any time * infants who have previously received levetiracetam * parents refuse consent * attending physician does not wish the infant to be enrolled in the study * infants who are currently receiving an investigational drug

Keywords: seizures neonate levetiracetam epilepsy central nervous system diseases anticonvulsants